A pre-clinical, preliminary 28-day study of XANGO Juice identified the bioavailability of xanthones to determine how many xanthones the body actually absorbs and the pathway they travel.
Michael W. Pugh, B.S., director of XANGO’s Product Development department. Michael Pugh has more than 15 years experience in the natural products industry and is currently head of research and development for XANGO, LLC. In this capacity, Pugh has implemented safety studies, initiated analytical work and validation, established pharmacokinetics and oversees all clinical work.
Charles River Laboratories, a pre-clinical lab that was established in 1947. It is world renowned for its research models in safety, pharmacokinetics, and in-vitro work. It employs 7,500 employees, including 500 researchers that include PhDs, MDs and DVMs.
The validated plasma method used LC-MS/MS technique to identify and quantify the amounts of alpha-mangostin in the plasma. This new analysis can quantify levels as low as 1 nanogram per ml (ng/ml).
The preliminary research demonstrates that the body absorbs xanthones in low dosages and that very high levels of xanthone consumption actually result in decreased absorption efficiency. In addition, preliminary results showed long-term daily consumption of XANGO Juice increases the levels of xanthones in the blood.
More specifically, the study showed the following regarding alpha-mangostin:
- In approximately 3.5 hours, the xanthone has been absorbed during digestion.
- Females have a more efficient absorption rate than males.
- Long-term consumption of XANGO Juice causes a blood loading effect.
- Alpha-mangostin is absorbed the way nature intended, at very low doses of consumption, such as the amount contained in XANGO Juice.
- At very high levels, the absorption efficiency of the xanthone decreases.
This study allows for a solid foundation for future clinical trials. Also, these preliminary findings show artificially inflating a product with xanthone extracts does not add any value.